Deoxycholic Acid CAS 83-44-3 Purity >98.0% (T) (HPLC)

Deoxycholic Acid (CAS: 83-44-3) is usually conjugated with glycine or taurine and acts as a detergent in the emulsification of fats for intestinal absorption.
Deoxycholic Acid was developed by Kythera biopharpharmaceuticals, Inc., in April 2015 by the U. S. Food and Drug Administration (FDA). Approved as the first local lipid-dissolving drug in the world. Deoxycholic acid is a kind of free bile acid existing in bile, which has strong surface activity, can destroy and dissolve cell membrane, and reduce the dissolution of small local subcutaneous fat. In clinical trials, deoxycholic acid was effective in eliminating submental fat and improving overall appearance compared to placebo.
Deoxycholic Acid is a secondary bile acid involved in the emulsification and solubilization of dietary fat. A 10 mg/mL injectable solution of chemically synthesized Deoxycholic Acid is indicated in various countries, including the USA (KybellaTM)[9] and several within Europe/the EU (BelkyraTM) to improve the appearance of moderate to severe submental convexity or fullness associated with SMF in adults, where it is currently the only approved minimally invasive treatment for submental contouring.
Sodium Deoxycholate, the sodium salt of Deoxycholic Acid, is often used as a biological detergent to lyse cells and solubilise cellular and membrane components.